GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Neptunus Interlong Bio-Technique Co Ltd (HKSE:08329) » Definitions » Cyclically Adjusted Revenue per Share

Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Cyclically Adjusted Revenue per Share : HK$0.00 (As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Shenzhen Neptunus Interlong Bio-Technique Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Shenzhen Neptunus Interlong Bio-Technique Co's adjusted revenue per share for the three months ended in Jun. 2024 was HK$0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is HK$0.00 for the trailing ten years ended in Jun. 2024.

During the past 12 months, Shenzhen Neptunus Interlong Bio-Technique Co's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Shenzhen Neptunus Interlong Bio-Technique Co was 7.60% per year. The lowest was 4.90% per year. And the median was 5.80% per year.

As of today (2025-01-18), Shenzhen Neptunus Interlong Bio-Technique Co's current stock price is HK$0.16. Shenzhen Neptunus Interlong Bio-Technique Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was HK$0.00. Shenzhen Neptunus Interlong Bio-Technique Co's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shenzhen Neptunus Interlong Bio-Technique Co was 1.33. The lowest was 0.21. And the median was 0.41.


Shenzhen Neptunus Interlong Bio-Technique Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Shenzhen Neptunus Interlong Bio-Technique Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Neptunus Interlong Bio-Technique Co Cyclically Adjusted Revenue per Share Chart

Shenzhen Neptunus Interlong Bio-Technique Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 0.58 0.61 0.64 0.67

Shenzhen Neptunus Interlong Bio-Technique Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.65 0.66 0.67 -

Competitive Comparison of Shenzhen Neptunus Interlong Bio-Technique Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Neptunus Interlong Bio-Technique Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen Neptunus Interlong Bio-Technique Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Neptunus Interlong Bio-Technique Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Shenzhen Neptunus Interlong Bio-Technique Co's Cyclically Adjusted PS Ratio falls into.



Shenzhen Neptunus Interlong Bio-Technique Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Shenzhen Neptunus Interlong Bio-Technique Co's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0/117.2957*117.2957
=0.000

Current CPI (Jun. 2024) = 117.2957.

Shenzhen Neptunus Interlong Bio-Technique Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.124 96.409 0.151
201409 0.122 97.948 0.146
201412 0.127 99.707 0.149
201503 0.112 99.927 0.131
201506 0.133 99.267 0.157
201509 0.119 99.927 0.140
201512 0.163 102.015 0.187
201603 0.101 102.785 0.115
201606 0.135 101.686 0.156
201609 0.122 102.565 0.140
201612 0.166 103.225 0.189
201703 0.107 103.335 0.121
201706 0.128 103.664 0.145
201709 0.146 103.994 0.165
201712 0.167 104.984 0.187
201803 0.151 105.973 0.167
201806 0.145 106.193 0.160
201809 0.150 106.852 0.165
201812 0.164 107.622 0.179
201903 0.151 108.172 0.164
201906 0.175 109.601 0.187
201909 0.189 110.260 0.201
201912 0.210 110.700 0.223
202003 0.128 110.920 0.135
202006 0.173 110.590 0.183
202009 0.204 107.512 0.223
202012 0.192 109.711 0.205
202103 0.156 111.579 0.164
202106 0.124 111.360 0.131
202109 0.148 109.051 0.159
202112 0.177 112.349 0.185
202203 0.158 113.558 0.163
202206 0.156 113.448 0.161
202209 0.167 113.778 0.172
202212 0.198 114.548 0.203
202303 0.203 115.427 0.206
202306 0.167 115.647 0.169
202309 0.171 116.087 0.173
202312 0.158 117.296 0.158
202406 0.000 117.296 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Shenzhen Neptunus Interlong Bio-Technique Co  (HKSE:08329) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Shenzhen Neptunus Interlong Bio-Technique Co was 1.33. The lowest was 0.21. And the median was 0.41.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Shenzhen Neptunus Interlong Bio-Technique Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Shenzhen Neptunus Interlong Bio-Technique Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhen Neptunus Interlong Bio-Technique Co Business Description

Traded in Other Exchanges
N/A
Address
95 Queensway, 18th Floor, United Centre, Admiralty, Hong Kong, HKG
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sales of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines; and the Sales and distribution of medicines and healthcare products. The majority of revenue is generated from the Manufacturing and selling of medicines.

Shenzhen Neptunus Interlong Bio-Technique Co Headlines

No Headlines